Health Care/Hospital
Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India
BEIJING, May 13, 2021 /PRNewswire/ -- Beijing Time May 10, 2021 — Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) and Shenzhen Pregene Biopharma Co., Ltd. today announced an agreement whereby Dr Reddy's will acquire an exclusive license in the Republic ofInd...
2021-05-13 15:21
1423
Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities
BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ -- Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-we...
2021-05-13 13:00
1427
Amorepacific Discovers Skin Barrier Regulator EGR3
* At the Society for Investigative Dermatology's e-poster talk session held on the 5th, Amorepacific announced the results of its skin barrier-related research. * Amorepacific has discovered EGR3 and identified its epigenetic regulation mechanism through the analysis of big data in the bio fi...
2021-05-13 10:31
2464
Ascentage Pharma (6855.HK) Becomes a Constituent of MSCI China Small Cap Index
SUZHOU, China and ROCKVILLE, Md., May 13, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that according to the latest ...
2021-05-13 08:28
1745
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
SHANGHAI and HONG KONG, May 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-05-13 08:00
2610
Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 in patients with mild COVID-19
Product recently cleared in EU as Class III medical device BALERNA, Switzerland, May 13, 2021 /PRNewswire/ -- APR Applied Pharma Research s.a. (APR), a leader in the development of pharmaceutical drug delivery technologies and systems and innovative products derived thereof, today announced the ...
2021-05-13 00:48
2129
Sysmex and ThinkCyte Agree on Joint Development and Capital Alliance
TOKYO, May 12, 2021 /PRNewswire/ -- Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO:Hisashi Ietsugu) and ThinkCyte, Inc. (HQ: Bunkyo-ku, Tokyo, Japan; CEO: Waichiro Katsuda) announced today the signing of joint development and investment agreements duringMay 2021 for the commercializatio...
2021-05-12 22:00
1556
CGTN: How China's people-centered approach works in fight against COVID-19
BEIJING, May 12, 2021 /PRNewswire/ -- The year of 2020 brought one of the toughest tests in modern history as a deadly pandemic wreaked havoc across the world, turning people's lives upside down.China, the world's most populous country, quickly waged a "people's war" against COVID-19 and vowed to...
2021-05-12 20:23
2754
Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing
Technology, industry collaborations and a desire to innovate will help participants sustain their growth momentum and achieve manufacturing scale, finds Frost & Sullivan SANTA CLARA, Calif., May 12, 2021 /PRNewswire/ -- The biopharmaceutical industry is facing its biggest test in recent times. A...
2021-05-12 18:12
1340
Ping An Completes $200 Million First Close of Voyager Partners Fintech and Digital Health Fund
HONG KONG and SHANGHAI, May 12, 2021 /PRNewswire/ -- Ping An Insurance (Group) Company ofChina, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318) today announced the initial close of Ping An Voyager Partners, LP, a growth stage venture fund that will make investments in fintech, ...
2021-05-12 18:03
11136
Chinese Companies Gear up to Expand to Europe with TOJOY
BEIJING, May 12, 2021 /PRNewswire/ -- Three high-tech companies from China recently signed with global business accelerator TOJOY to expand their businesses throughoutEurope. TOJOY Europe recently announced partnerships with Hongtian Langjie Environmental Protection Tech, Jimuyida Sciences, and ...
2021-05-12 15:27
1543
Regent Pacific's Unrealised Gain in Venturex Resources Limited Increased to US$10.74 million
Highlights: Unrealised Gain in Venturex Resources Limited * Regent Pacific's investment in Venturex Resources Limited has increased significantly toUS$10.74 million (approximately HK$83.77 million) and a marked to-market value ofUS$13.13 million (approximately HK$102.41million) on its VXR sha...
2021-05-12 15:04
6511
CStone Announces Acceptance of New Drug Application in Hong Kong for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumor
SUZHOU, China, May 12, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced the acceptance of the company's new ...
2021-05-12 14:09
2604
ScentAir: Masters of enhancing customer experiences on behalf of brands through scent marketing #ScentedMoments
SINGAPORE, May 12, 2021 /PRNewswire/ -- For more than 25 years, ScentAir, the global leader in scent marketing, has helped hotel, real estate and business industry leaders across the globe create engaged customer experiences and emotional connections using fragrances. Their goal of bringing fragr...
2021-05-12 12:00
2993
PMB and CEA Announce the Commissioning of iMiGiNE at Frederic Joliot Hospital (Orsay), Paving the Way for Next Generation Molecular Imaging Diagnostics
PEYNIER, France, May 12, 2021 /PRNewswire/ -- An automated radiopharmaceutical production system iMiGiNE has been installed in Frederic Joliot Hospital (CEA) in Orsay,France and commissioned in December 2020. This disruptive system will revolutionize the radiopharmaceutical production, access and...
2021-05-12 08:45
1758
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
* Secured strongest-ever balance sheet with approximately $33.1 million in cash * Strengthened the Company's leadership team to drive commercial focus * Expanded the Company's intellectual property portfolio * Initiated production of product components at scale at the Company's Silver One ...
2021-05-12 04:10
5604
Shaemus Gleason Appointed Executive Vice President US Operations at Clarity Pharmaceuticals
SYDNEY, May 11, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment ofShaemus Gleason as Executive Vice President U.S. Operations as the company expands its presence, clinica...
2021-05-11 21:04
1605
CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences
MONTREAL, May 11, 2021 /PRNewswire/ -- CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ("Reveal"), aSan Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative ...
2021-05-11 20:21
1785
New Global Addiction Recovery and Overdose Prevention App
BETTER App Available for Download TODAY
VANCOUVER, May 11, 2021 /PRNewswire/ -- A new mobile app has been developed
to connect people around the world who are seeking recovery from addiction with
a support community that wants to help - potentially saving lives.
2021-05-11 19:00
1159
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 11, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian pati...
2021-05-11 18:10
5039
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 289 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 253 media titles]
2024-04-30 15:13Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
12314
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
7944
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
7544
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
7480
